Brought to you by 
Roche acquires InterMune for $8bn
10 Sep 2020
Executive Summary
In an all-cash deal Roche acquired former partner, public biotech InterMune Inc. (orphan respiratory/pulmonary and fibrotic disease therapeutics), for $8bn or $74 per share--a 47% premium and almost 114 times the smaller company’s 2013 revenues of $70mm. It’s rumored, but not confirmed, that Roche beat out other Big Pharma suitors including Sanofi, GSK, and Novartis, as well as Actelion, and first-tier biotech Gilead Sciences.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche acquires InterMune for $8bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice